IVA earnings: next report 2026-09-25, real EPS beat/miss history, analyst consensus Buy, P/E -2.01. Updated 2026-07-23.
Inventiva (IVA) Research Hub
Inventiva (IVA) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.02 USD (-9.66%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.01, market cap 0.23B. This hub links to the full technical, earnings and options research available for IVA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 4.02 USD (-9.66%) |
| 52-week range | 3.35 USD – 5.1 USD |
| Trend regime | Range |
| 14-day RSI | 26.2 (Oversold) |
| Trailing P/E | -2.01 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-25 |
Available research for IVA
Covered Call on IVA: how it works, illustrative setup around the real 4.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IVA: how it works, illustrative setup around the real 4.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IVA: how it works, illustrative setup around the real 4.02 USD price, max profit/loss, breakeven and when to use it. Educational.
IVA technical analysis: range, last 4.02 USD, RSI 26.2, 52w range 3.35 USD–5.1 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IVA in?
Inventiva (IVA) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.
Is IVA in an uptrend or downtrend?
As of 2026-09-11, IVA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IVA's trailing P/E ratio?
IVA's trailing P/E is -2.01, with a market cap of 0.23B. See the earnings research page for full valuation detail.
When does IVA next report earnings?
IVA is next scheduled to report earnings on 2026-09-25, with a consensus EPS estimate of -0.41947 USD.